Agios' IDH Inhibitors Show Their Mettle At ASH

Updates for key products from Agios bring comfort for analysts as it forges ahead with a filing and new studies in AML. Another of its investigational products is also showing first-in-class potential in pyruvate kinase deficiency.

Agios Pharmaceuticals Inc. is tilting at a year-end US approval filing for its first-in-class, oral, targeted inhibitor of the mutant IDH1 enzyme, ivosidenib, for acute myeloid leukemia (AML) as it presented new data at the American Society of Hematology meeting.

Buoyed by the recent early approval of its and partner Celgene Corp.'s oral, targeted inhibitor of isocitrate dehydrogenase-2 (IDH2),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D